Fibroproliferative scars.
Fibroproliferative scars remain an ongoing clinical challenge. Both hypertrophic scars and keloids require multimodal therapy toachieve partally successful treatment. At the present time incomplete understanding about the pathogenesis of fibroproliferative scars makes targeted, mechanistic treatment impossible. As understanding of these abnormal wound problems increases, more effective treatments will likely be available. Until that time, clinicians must utilize existing knowledge to treat patients while continuing to experiment with new approaches.
Rahban
Shahrad R
SR
University of Southern California Keck School of Medicine, Division of Plastic and Reconstructive Surgery, LAC+ USC Medical Center, 1450 San Pablo Street, Suite #2000, Los Angeles, CA 90033, USA.
Garner
Warren L
WL
D002921:Cicatrix / Q000473:pathology / Q000503:physiopathology* / Q000628:therapy; D017439:Cicatrix, Hypertrophic / Q000473:pathology / Q000503:physiopathology / Q000628:therapy; D005355:Fibrosis / Q000473:pathology; D006801:Humans; D007627:Keloid / Q000473:pathology / Q000503:physiopathology / Q000628:therapy; D014945:Wound Healing / Q000502:physiology*